The sodium-glucose co-transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor-β. - Lyu TT; Wang JY; Tan JS; Li TQ; Shu YY; Yang Y (British journal of pharmacology, 2026)